Filing Details

Accession Number:
0001567619-19-005004
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-02-20 17:01:28
Reporting Period:
2019-02-15
Accepted Time:
2019-02-20 17:01:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874716 Idexx Laboratories Inc IDXX In Vitro & In Vivo Diagnostic Substances (2835) 010393723
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1526223 Jacqueline Studer One Idexx Drive
Westbrook ME 04092
Cvp, Gen. Counsel & Secretary No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-02-15 2,866 $79.54 8,648 No 4 M Direct
Common Stock Disposition 2019-02-15 2,866 $207.54 5,762 No 4 S Direct
Common Stock Acquisiton 2019-02-15 100 $79.54 5,862 No 4 M Direct
Common Stock Disposition 2019-02-15 100 $207.80 5,762 No 4 S Direct
Common Stock Acquisiton 2019-02-15 4,700 $67.85 10,462 No 4 M Direct
Common Stock Disposition 2019-02-15 4,700 $208.54 5,762 No 4 S Direct
Common Stock Acquisiton 2019-02-15 1 $67.85 5,763 No 4 M Direct
Common Stock Disposition 2019-02-15 1 $208.90 5,762 No 4 S Direct
Common Stock Acquisiton 2019-02-15 2,219 $141.60 7,981 No 4 M Direct
Common Stock Disposition 2019-02-15 2,219 $208.95 5,762 No 4 S Direct
Common Stock Acquisiton 2019-02-15 1,714 $178.26 7,476 No 4 M Direct
Common Stock Disposition 2019-02-15 1,714 $209.18 5,762 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right-to-buy) Disposition 2019-02-15 2,866 $0.00 2,866 $79.54
Common Stock Incentive Stock Option (right-to-buy) Disposition 2019-02-15 100 $0.00 100 $79.54
Common Stock Non-Qualified Stock Option (right-to-buy) Disposition 2019-02-15 4,700 $0.00 4,700 $67.85
Common Stock Incentive Stock Option (right-to-buy) Disposition 2019-02-15 1 $0.00 1 $67.85
Common Stock Non-Qualified Stock Option (right-to-buy) Disposition 2019-02-15 2,219 $0.00 2,219 $141.60
Common Stock Non-Qualified Stock Option (right-to-buy) Disposition 2019-02-15 1,714 $0.00 1,714 $178.26
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
2,866 2025-02-13 No 4 M Direct
1,864 2025-02-13 No 4 M Direct
7,927 2026-02-13 No 4 M Direct
1,474 2026-02-13 No 4 M Direct
5,948 2027-02-13 No 4 M Direct
6,293 2028-02-13 No 4 M Direct
Footnotes
  1. Represents the weighted average sales price of the shares sold ranging from a low of $207.08 to a high of $208.76 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  2. Represents the weighted average sales price of the shares sold ranging from a low of $207.81 to a high of $208.90 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  3. Represents the weighted average sales price of the shares sold ranging from a low of $208.91 to a high of $209.09 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  4. Represents the weighted average sales price of the shares sold ranging from a low of $209.10 to a high of $209.37 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  5. Grant of option to buy 7,165 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five annual installments beginning on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
  6. Grant of option to buy 3,140 shares of Issuer common stock that vests and is exercisable in five annual installments beginning on February 14, 2016, without giving effect to Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
  7. Grant of option to buy shares of Issuer common stock exercisable in five annual installments beginning February 14, 2017.
  8. Grant of option to buy shares of Issuer common stock exercisable in five annual installments beginning February 14, 2018.
  9. Grant of option to buy shares of Issuer common stock exercisable in five annual installments beginning February 14, 2019.
  10. Not applicable.